Key Points
- EVP Ryan Savitz sold 8,224 shares on April 9 at an average price of $89.84 under a pre-arranged Rule 10b5-1 plan, cutting his stake by 50%; he also sold 114,367 shares on March 31 at $83.00.
- Dianthus reported ($1.43) EPS for the quarter, missing estimates and showing large negative margins, while the stock trades near recent highs with a market cap of about $3.99 billion.
- Wall Street is largely bullish—most analysts rate the stock Buy/Strong Buy with an average target of $115.55 and some targets as high as $145.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 8,224 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the sale, the executive vice president owned 8,224 shares of the company's stock, valued at $738,844.16. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Savitz also recently made the following trade(s):
- On Tuesday, March 31st, Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00.
Dianthus Therapeutics Trading Down 2.1%
Shares of DNTH stock opened at $89.77 on Friday. The stock has a 50 day moving average of $67.46 and a two-hundred day moving average of $49.70. Dianthus Therapeutics, Inc. has a 12 month low of $15.25 and a 12 month high of $92.27. The company has a market capitalization of $3.99 billion, a P/E ratio of -21.90 and a beta of 1.22.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. Sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Dianthus Therapeutics
Hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $27,000. Parkside Financial Bank & Trust raised its holdings in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company's stock worth $37,000 after buying an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after buying an additional 3,317 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. Raymond James Financial upgraded Dianthus Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price objective for the stock from $63.00 to $123.00 in a research report on Tuesday, March 10th. Wolfe Research began coverage on Dianthus Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $98.00 price objective for the company. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 9th. Oppenheimer increased their target price on Dianthus Therapeutics to $145.00 and gave the stock an "outperform" rating in a report on Monday, March 9th. Finally, HC Wainwright increased their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a "buy" rating in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $115.55.
Check Out Our Latest Stock Analysis on DNTH
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
